Robert C Green

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1663546/publications.pdf

Version: 2024-02-01

236 papers	16,124 citations	34016 52 h-index	20307 116 g-index
269 all docs	269 docs citations	269 times ranked	22795 citing authors

#	Article	IF	Citations
1	Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression. Journal of Genetic Counseling, 2022, 31, 218-229.	0.9	5
2	Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 824-857.	0.4	56
3	Reevaluating the â€œright not to knowâ€• in genomics research. Genetics in Medicine, 2022, 24, 289-292.	1.1	2
4	Development of a clinical polygenic risk score assay and reporting workflow. Nature Medicine, 2022, 28, 1006-1013.	15.2	74
5	Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases. JAMA Oncology, 2022, 8, 835.	3.4	25
6	Parental Attitudes Toward Standard Newborn Screening and Newborn Genomic Sequencing: Findings From the BabySeq Study. Frontiers in Genetics, 2022, 13, 867371.	1.1	19
7	Genetic counseling following directâ€to consumer genetic testing: Consumer perspectives. Journal of Genetic Counseling, 2021, 30, 329-334.	0.9	14
8	Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. Genetics in Medicine, 2021, 23, 603-605.	1.1	29
9	The limits of acceptable political influence over the FDA. Nature Medicine, 2021, 27, 188-190.	15.2	7
10	Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines. JAMA - Journal of the American Medical Association, 2021, 325, 221.	3.8	20
11	An ethics framework for consolidating and prioritizing COVID-19 clinical trials. Clinical Trials, 2021, 18, 226-233.	0.7	13
12	Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. Genetics in Medicine, 2021, 23, 1366-1371.	1.1	16
13	DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 979-988.	1.1	14
14	Allocating scarce life-saving resources: the proper role of age. Journal of Medical Ethics, 2021, 47, 836-838.	1.0	8
15	Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project. Genetics in Medicine, 2021, 23, 1372-1375.	1.1	47
16	Prospect of Direct Benefit in Pediatric Trials: Practical Challenges and Potential Solutions. Pediatrics, 2021, 147, .	1.0	13
17	Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials. Journal of Infectious Diseases, 2021, 224, 1995-2000.	1.9	19
18	Development and Validation of a Comprehensive Genomics Knowledge Scale. Public Health Genomics, 2021, 24, 291-303.	0.6	5

#	Article	IF	Citations
19	Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nature Medicine, 2021, 27, 1012-1024.	15.2	109
20	Primary care providersâ€™ responses to unsolicited Lynch syndrome secondary findings of varying clinical significance. Genetics in Medicine, 2021, 23, 1977-1983.	1.1	4
21	Historical trends in health care-related financial holdings among members of Congress. PLoS ONE, 2021, 16, e0253624.	1.1	0
22	An international policy on returning genomic research results. Genome Medicine, 2021, 13, 115.	3.6	28
23	Molecular cancer screening: in search of evidence. Nature Medicine, 2021, 27, 1139-1142.	15.2	14
24	Return of individual research results: What do participants prefer and expect?. PLoS ONE, 2021, 16, e0254153.	1.1	10
25	Psychosocial Effect of Newborn Genomic Sequencing on Families in the BabySeq Project. JAMA Pediatrics, 2021, 175, 1132.	3.3	35
26	Physician-directed genetic screening to evaluate personal risk for medically actionable disorders: a large multi-center cohort study. BMC Medicine, 2021, 19, 199.	2.3	17
27	Behavioral and psychological impact of genome sequencing: a pilot randomized trial of primary care and cardiology patients. Npj Genomic Medicine, 2021, 6, 72.	1.7	3
28	Polygenic risk scores in the clinic: Translating risk into action. Human Genetics and Genomics Advances, 2021, 2, 100047.	1.0	26
29	Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Medicine, 2021, 13, 14.	3.6	79
30	Return of individual research results from genomic research: A systematic review of stakeholder perspectives. PLoS ONE, 2021, 16, e0258646.	1.1	32
31	Returning actionable genomic results in a research biobank: Analytic validity, clinical implementation, and resource utilization. American Journal of Human Genetics, 2021, 108, 2224-2237.	2.6	34
32	GA4GH: International policies and standards for data sharing across genomic research and healthcare. Cell Genomics, 2021, 1, 100029.	3.0	94
33	How knowledge of elevated amyloid impacts neuropsychological performance in cognitively normal older adults: Findings from the REVEAL SCAN Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
34	Predictive and Precision Medicine with Genomic Data. Clinical Chemistry, 2020, 66, 33-41.	1.5	7
35	The case for implementing sustainable routine, population-level genomic reanalysis. Genetics in Medicine, 2020, 22, 815-816.	1.1	11
36	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. Bone Marrow Transplantation, 2020, 55, 906-917.	1.3	33

#	Article	IF	Citations
37	Regulatory flexibility for COVID-19 research. Journal of Law and the Biosciences, 2020, 7, lsaa057.	0.8	18
38	Educating military primary health-care providers in genomic medicine: lessons learned from the MilSeq Project. Genetics in Medicine, 2020, 22, 1710-1717.	1.1	7
39	COVID-19 Moves Medicine into a Virtual Space. Annals of Surgery, 2020, 272, e159-e160.	2.1	15
40	Airmen and health-care providersâ€™ attitudes toward the use of genomic sequencing in the US Air Force: findings from the MilSeq Project. Genetics in Medicine, 2020, 22, 2003-2010.	1.1	2
41	The formation of the advisory group on risk evaluation education for dementia. Alzheimer's and Dementia, 2020, 16, e045562.	0.4	2
42	Pediatric reporting of genomic results study (PROGRESS): a mixed-methods, longitudinal, observational cohort study protocol to explore disclosure of actionable adult- and pediatric-onset genomic variants to minors and their parents. BMC Pediatrics, 2020, 20, 222.	0.7	11
43	Multiple GYPB gene deletions associated with the Uâˆ’ phenotype in those of African ancestry. Transfusion, 2020, 60, 1294-1307.	0.8	12
44	Returning Results in the Genomic Era: Initial Experiences of the eMERGE Network. Journal of Personalized Medicine, 2020, 10, 30.	1.1	39
45	Genomeâ€wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways. Alzheimer's and Dementia, 2020, 16, 1134-1145.	0.4	28
46	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	6.0	450
47	Disclosing genetic risk for Alzheimer's dementia to individuals with mild cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12002.	1.8	16
48	Ethical and Regulatory Issues for Embedded Pragmatic Trials Involving People Living with Dementia. Journal of the American Geriatrics Society, 2020, 68, S37-S42.	1.3	12
49	Sharing Patient Data Without Exploiting Patients. JAMA - Journal of the American Medical Association, 2020, 323, 505.	3.8	22
50	Ethics and Resource Scarcity: ASCO Recommendations for the Oncology Community During the COVID-19 Pandemic. Journal of Clinical Oncology, 2020, 38, 2201-2205.	0.8	104
51	Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing. Value in Health, 2020, 23, 559-565.	0.1	6
52	Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol. JAMA Network Open, 2020, 3, e2027092.	2.8	22
53	The future of genomics in Ireland â€“ focus on genomics for health. HRB Open Research, 2020, 3, 89.	0.3	1
54	Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries. Nature Medicine, 2019, 25, 1198-1204.	15.2	46

#	Article	IF	Citations
55	Automated typing of red blood cell and platelet antigens from whole exome sequences. Transfusion, 2019, 59, 3253-3263.	0.8	32
56	Analyzing and Reanalyzing the Genome: Findings from the MedSeq Project. American Journal of Human Genetics, 2019, 105, 177-188.	2.6	38
57	Returning a Genomic Result for an Adult-Onset Condition to the Parents of a Newborn: Insights From the BabySeq Project. Pediatrics, 2019, 143, S37-S43.	1.0	45
58	Pay-to-Participate Trials and Vulnerabilities in Research Ethics Oversight. JAMA - Journal of the American Medical Association, 2019, 322, 1553.	3.8	6
59	Reconciling Opportunistic and Population Screening in Clinical Genomics. Mayo Clinic Proceedings, 2019, 94, 103-109.	1.4	26
60	Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies. Genetics in Medicine, 2019, 21, 2781-2790.	1.1	55
61	When Is It Ethical for Physician-Investigators to Seek Consent From Their Own Patients?. American Journal of Bioethics, 2019, 19, 11-18.	0.5	44
62	Patient-Physician Relationship in the Age of Expanded Access to Informationâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1633.	3.8	0
63	Challenges in Research on Suicide Preventionâ€"Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1105.	3.8	0
64	Predispositional genome sequencing in healthy adults: design, participant characteristics, and early outcomes of the PeopleSeq Consortium. Genome Medicine, 2019, 11, 10.	3.6	41
65	Association Between Financial Incentives and Participant Deception About Study Eligibility. JAMA Network Open, 2019, 2, e187355.	2.8	35
66	The Multidimensional Illness Severity Questionnaire: Preliminary evaluation of a brief parentâ€reported measure of illness severity. Journal of Paediatrics and Child Health, 2019, 55, 1241-1246.	0.4	2
67	Challenging the Current Recommendations for Carrier Testing in Children. Pediatrics, 2019, 143, S27-S32.	1.0	13
68	Perceived Benefits, Risks, and Utility of Newborn Genomic Sequencing in the BabySeq Project. Pediatrics, 2019, 143, S6-S13.	1.0	47
69	Preferences for Return of Genetic Results Among Participants in the Jackson Heart Study and Framingham Heart Study. Circulation Genomic and Precision Medicine, 2019, 12, e002632.	1.6	13
70	Consent for clinical genome sequencing: considerations from the Clinical Sequencing Exploratory Research Consortium. Personalized Medicine, 2019, 16, 325-333.	0.8	8
71	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	9.4	192
72	Parental interest in genomic sequencing of newborns: enrollment experience from the BabySeq Project. Genetics in Medicine, 2019, 21, 622-630.	1.1	61

#	Article	IF	Citations
73	Effect of communicating personalized rheumatoid arthritis risk on concern for developing RA: A randomized controlled trial. Patient Education and Counseling, 2019, 102, 976-983.	1.0	20
74	Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project. American Journal of Human Genetics, 2019, 104, 76-93.	2.6	176
75	A whole genome approach for discovering the genetic basis of blood group antigens: independent confirmation for P1 and Xg^a. Transfusion, 2019, 59, 908-915.	0.8	13
76	Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genetics in Medicine, 2019, 21, 1100-1110.	1.1	111
77	Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs. JAMA - Journal of the American Medical Association, 2018, 319, 2167.	3.8	7
78	How Primary Care Providers Talk to Patients about Genome Sequencing Results: Risk, Rationale, and Recommendation. Journal of General Internal Medicine, 2018, 33, 877-885.	1.3	16
79	Gender and Byline Placement of Co-first Authors in Clinical and Basic Science Journals With High Impact Factors. JAMA - Journal of the American Medical Association, 2018, 319, 610.	3.8	39
80	Patient understanding of, satisfaction with, and perceived utility of whole-genome sequencing: findings from the MedSeq Project. Genetics in Medicine, 2018, 20, 1069-1076.	1.1	58
81	Federal Right-to-Try Legislation â€" Threatening the FDAâ€™s Public Health Mission. New England Journal of Medicine, 2018, 378, 695-697.	13.9	39
82	Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping. Alzheimer's and Dementia, 2018, 14, 514-519.	0.4	14
83	Effectiveness of a Webâ€Based Personalized Rheumatoid Arthritis Risk Tool With or Without a Health Educator for Knowledge of Rheumatoid Arthritis Risk Factors. Arthritis Care and Research, 2018, 70, 1421-1430.	1.5	20
84	The impact of genetic counselorsâ€™ use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimerâ€™s disease. Patient Education and Counseling, 2018, 101, 817-823.	1.0	10
85	Characteristics Associated With Preferences for Parent-Centered Decision Making in Neonatal Intensive Care. JAMA Pediatrics, 2018, 172, 461.	3.3	37
86	Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genetics in Medicine, 2018, 20, 1544-1553.	1.1	25
87	A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genetics in Medicine, 2018, 20, 132-141.	1.1	36
88	Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial. Arthritis Care and Research, 2018, 70, 823-833.	1.5	60
89	Navigating the researchâ€"clinical interface in genomic medicine: analysis from the CSER Consortium. Genetics in Medicine, 2018, 20, 545-553.	1.1	34
90	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. Journal of Clinical Oncology, 2018, 36, 3331-3339.	0.8	58

#	Article	IF	Citations
91	Protecting clinical trial participants and study integrity in the age of social media. Cancer, 2018, 124, 4610-4617.	2.0	10
92	Beyond financial conflicts of interest: Institutional oversight of faculty consulting agreements at schools of medicine and public health. PLoS ONE, 2018, 13, e0203179.	1.1	5
93	Will my child do better if she enrolls in a clinical trial?. Cancer, 2018, 124, 3965-3968.	2.0	3
94	Implications of Zero Suicide for Suicide Prevention Research. JAMA - Journal of the American Medical Association, 2018, 320, 1633.	3.8	30
95	The New Age of Patient Autonomy. JAMA - Journal of the American Medical Association, 2018, 320, 1973.	3.8	82
96	Communication Predictors of Patient and Companion Satisfaction with Alzheimerâ€™s Genetic Risk Disclosure. Journal of Health Communication, 2018, 23, 807-814.	1.2	7
97	Approaches to carrier testing and results disclosure in translational genomics research: The clinical sequencing exploratory research consortium experience. Molecular Genetics & Genomic Medicine, 2018, 6, 898-909.	0.6	15
98	Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials. JAMA Oncology, 2018, 4, 1041.	3.4	4
99	Automated typing of red blood cell and platelet antigens: a whole-genome sequencing study. Lancet Haematology,the, 2018, 5, e241-e251.	2.2	70
100	Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. Biology of Blood and Marrow Transplantation, 2018, 24, 2145-2151.	2.0	14
101	The BabySeq project: implementing genomic sequencing in newborns. BMC Pediatrics, 2018, 18, 225.	0.7	115
102	Reconciling newborn screening and a novel splice variant in BTD associated with partial biotinidase deficiency: a BabySeq Project case report. Journal of Physical Education and Sports Management, 2018, 4, a002873.	0.5	7
103	Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project. Value in Health, 2018, 21, 1054-1061.	0.1	13
104	A collaborative translational research framework for evaluating and implementing the appropriate use of human genome sequencing to improve health. PLoS Medicine, 2018, 15, e1002631.	3.9	40
105	An integrated clinical program and crowdsourcing strategy for genomic sequencing and Mendelian disease gene discovery. Npj Genomic Medicine, 2018, 3, 21.	1.7	24
106	Informed Consent and the Role of the Treating Physician. New England Journal of Medicine, 2018, 378, 2433-2438.	13.9	20
107	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	5.8	250
108	Newborn Sequencing in Genomic Medicine and Public Health. Pediatrics, 2017, 139, .	1.0	174

#	Article	IF	Citations
109	A taxonomy of medical uncertainties in clinical genome sequencing. Genetics in Medicine, 2017, 19, 918-925.	1.1	91
110	Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest. JAMA Internal Medicine, 2017, 177, 344.	2.6	93
111	A curated gene list for reporting results of newborn genomic sequencing. Genetics in Medicine, 2017, 19, 809-818.	1.1	79
112	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine, 2017, 19, 787-795.	1.1	46
113	When bins blur: Patient perspectives on categories of results from clinical whole genome sequencing. AJOB Empirical Bioethics, 2017, 8, 82-88.	0.8	34
114	Ethical considerations in genomic testing for hematologic disorders. Blood, 2017, 130, 460-465.	0.6	22
115	From Sequence Data to Returnable Results: Ethical Issues in Variant Calling and Interpretation. Genetic Testing and Molecular Biomarkers, 2017, 21, 178-183.	0.3	5
116	The price of whole-genome sequencing may be decreasing, but who will be sequenced?. Personalized Medicine, 2017, 14, 203-211.	0.8	7
117	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine, 2017, 14, 37-50.	0.8	15
118	Disclosing genetic risk of Alzheimerâ€™s disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Education and Counseling, 2017, 100, 927-935.	1.0	18
119	Personal Genomic Testing for Cancer Risk: Results From the Impact of Personal Genomics Study. Journal of Clinical Oncology, 2017, 35, 636-644.	0.8	34
120	A Comparison of Whole Genome Sequencing to Multigene Panel Testing in Hypertrophic Cardiomyopathy Patients. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	62
121	Justification and authority in institutional review board decision letters. Social Science and Medicine, 2017, 194, 25-33.	1.8	19
122	Communication challenges for nongeneticist physicians relaying clinical genomic results. Personalized Medicine, 2017, 14, 423-431.	0.8	36
123	Racial minority group interest in direct-to-consumer genetic testing: findings from the PGen study. Journal of Community Genetics, 2017, 8, 293-301.	0.5	22
124	Preferences for the Return of Individual Results From Research on Pediatric Biobank Samples. Journal of Empirical Research on Human Research Ethics, 2017, 12, 97-106.	0.6	19
125	The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients. Annals of Internal Medicine, 2017, 167, 159.	2.0	145
126	Diet and exercise changes following direct-to-consumer personal genomic testing. BMC Medical Genomics, 2017, 10, 24.	0.7	25

#	Article	IF	Citations
127	Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) Study. Genetics in Medicine, 2017, 19, 537-545.	1.1	39
128	Implementing cost transparency in oncology: A qualitative study of barriers, facilitators, and patient preferences.. Journal of Clinical Oncology, 2017, 35, 6597-6597.	0.8	5
129	Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS Medicine, 2017, 14, e1002190.	3.9	62
130	An eMERGE Clinical Center at Partners Personalized Medicine. Journal of Personalized Medicine, 2016, 6, 5.	1.1	31
131	A randomized trial Examining The Impact Of Communicating Genetic And Lifestyle Risks For Obesity. Obesity, 2016, 24, 2481-2490.	1.5	8
132	Ethics knowledge of recent paediatric residency graduates: the role of residency ethics curricula. Journal of Medical Ethics, 2016, 42, 809-814.	1.0	14
133	Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease. Annals of Internal Medicine, 2016, 164, 155.	2.0	34
134	Clinical Trials Infrastructure as a Quality Improvement Intervention in Low- and Middle-Income Countries. American Journal of Bioethics, 2016, 16, 3-11.	0.5	35
135	Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 645-653.	0.4	72
136	When Participants in Genomic Research Grow Up: Contact and Consent atÂthe Age of Majority. Journal of Pediatrics, 2016, 168, 226-231.e1.	0.9	17
137	Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. AJOB Empirical Bioethics, 2016, 7, 106-115.	0.8	16
138	Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. American Journal of Human Genetics, 2016, 98, 1067-1076.	2.6	432
139	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics, 2016, 98, 1051-1066.	2.6	137
140	The impact of personal genomics on risk perceptions and medical decision-making. Nature Biotechnology, 2016, 34, 912-918.	9.4	23
141	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
142	Parental Decision-Making Preferences in Neonatal Intensive Care. Journal of Pediatrics, 2016, 179, 36-41.e3.	0.9	49
143	Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. Transfusion, 2016, 56, 743-754.	0.8	81
144	Procedure-specific consent is the norm in United States intensive care units. Intensive Care Medicine, 2016, 42, 1637-1638.	3.9	3

#	Article	IF	Citations
145	Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. Science Translational Medicine, 2016, 8, 364ra151.	5.8	55
146	Family health history reporting is sensitive to small changes in wording. Genetics in Medicine, 2016, 18, 1308-1311.	1.1	6
147	Genomic medicine in the military. Npj Genomic Medicine, 2016, 1, 15008.	1.7	25
148	Reclassification of genetic-based risk predictions as GWAS data accumulate. Genome Medicine, 2016, 8, 20.	3.6	26
149	Toward clinical genomics in everyday medicine: perspectives and recommendations. Expert Review of Molecular Diagnostics, 2016, 16, 521-532.	1.5	58
150	â€œBig dataâ€•gets personal. Science Translational Medicine, 2016, 8, 322fs3-3fs3.	5.8	4
151	Patientsâ€™ perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project. Personalized Medicine, 2016, 13, 13-20.	0.8	31
152	Psychosocial Factors Influencing Parental Interest in Genomic Sequencing of Newborns. Pediatrics, 2016, 137, S30-S35.	1.0	17
153	Oncologistsâ€™ and cancer patientsâ€™ views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine, 2016, 18, 1011-1019.	1.1	108
154	Brain pathologies in extreme old age. Neurobiology of Aging, 2016, 37, 1-11.	1.5	94
155	The Role of Patient Perspectives in Clinical Research Ethics and Policy: Response to Open Peer Commentaries on â€œPatient Perspectives on the Learning Health Systemâ€• American Journal of Bioethics, 2016, 16, W7-W9.	0.5	1
156	Adopting genetics: motivations and outcomes of personal genomic testing in adult adoptees. Genetics in Medicine, 2016, 18, 924-932.	1.1	39
157	Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates. Circulation, 2016, 133, 1181-1188.	1.6	198
158	Participants and Study Declinersâ€™ Perspectives About the Risks of Participating in a Clinical Trial of Whole Genome Sequencing. Journal of Empirical Research on Human Research Ethics, 2016, 11, 21-30.	0.6	41
159	Consumers report lower confidence in their genetics knowledge following direct-to-consumer personal genomic testing. Genetics in Medicine, 2016, 18, 65-72.	1.1	71
160	Deliberations of a precision medicine tumor board.. Journal of Clinical Oncology, 2016, 34, e13005-e13005.	0.8	1
161	Genomic sequencing in clinical practice: applications, challenges, and opportunities. Dialogues in Clinical Neuroscience, 2016, 18, 299-312.	1.8	59
162	IC-P-042: Influence of rare reelin variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease. , 2015, 11, P36-P36.		1

#	Article	IF	Citations
163	P1-201: Genetic findings using ADNI multimodal quantitative phenotypes: A 2014 update. , 2015, 11, P426-P426.		1
164	P3-014: Influence of rare RELN variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease. , 2015, 11, P624-P625.		0
165	Child and Parent Understanding of Clinical Trials: The Semi-Structured Comprehension Interview. AJOB Empirical Bioethics, 2015, 6, 23-32.	0.8	4
166	O4-05-01: Gwas of longitudinal amyloid PET identifies IL1RAP as a new potential Alzheimer's disease target. , 2015, 11, P277-P278.		0
167	Explaining, not just predicting, drives interest in personal genomics. Genome Medicine, 2015, 7, 74.	3.6	28
168	Disclosing Secondary Findings from Pediatric Sequencing to Families: Considering the â€œBenefit to Familiesâ€. Journal of Law, Medicine and Ethics, 2015, 43, 552-558.	0.4	53
169	Participant Satisfaction With a Preference-Setting Tool for the Return of Individual Research Results in Pediatric Genomic Research. Journal of Empirical Research on Human Research Ethics, 2015, 10, 414-426.	0.6	19
170	The impact of direct-to-consumer personal genomic testing on perceived risk of breast, prostate, colorectal, and lung cancer: findings from the PGen study. BMC Medical Genomics, 2015, 8, 63.	0.7	17
171	A One-Page Summary Report of Genome Sequencing for the Healthy Adult. Public Health Genomics, 2015, 18, 123-129.	0.6	37
172	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.0	27
173	The Development of a Preference-Setting Model for the Return of Individual Genomic Research Results. Journal of Empirical Research on Human Research Ethics, 2015, 10, 107-120.	0.6	25
174	Reply to S. Gupta et al. Journal of Clinical Oncology, 2015, 33, 1414-1414.	0.8	9
175	Physicians and Insider Trading. JAMA Internal Medicine, 2015, 175, 1955.	2.6	4
176	Gatekeepers for pragmatic clinical trials. Clinical Trials, 2015, 12, 442-448.	0.7	32
177	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. Biology of Blood and Marrow Transplantation, 2015, 21, 1308-1314.	2.0	45
178	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 1815-1822.	2.0	13
179	P1-139: Using the capacity assessment tool for genetic testing (CAT-GT) to assess the ability of persons with MCI to decide about ApoE testing: The reveal study. , 2015, 11, P395-P396.		1
180	P2-016: Identification of genetic variants associated with Alzheimer's disease: Progression rate. , 2015, 11, P487-P487.		0

#	Article	IF	Citations
181	F3-03-01: Disclosing ApoE genotype status to individuals at risk for Alzheimer's disease: Applying lessons learned from the reveal study to prevention treatment trials. , 2015, 11, P214-P214.		0
182	O3-13-04: Genome-wide rare variant analysis identifies candidate genes significantly associated with composite scores for memory. , 2015, 11, P251-P252.		1
183	â€˜Someday it will be the normâ€™: physician perspectives on the utility of genome sequencing for patient care in the MedSeqProject. Personalized Medicine, 2015, 12, 23-32.	0.8	40
184	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	13.7	772
185	Clinical research: Should patients pay to play?. Science Translational Medicine, 2015, 7, 298ps16.	5.8	22
186	Commentary on Hey and Kimmelman. Clinical Trials, 2015, 12, 116-118.	0.7	14
187	GINA, Genetic Discrimination, and Genomic Medicine. New England Journal of Medicine, 2015, 372, 397-399.	13.9	141
188	Ethical Testing of Experimental Ebola Treatmentsâ€”Reply. JAMA - Journal of the American Medical Association, 2015, 313, 422.	3.8	1
189	How to know when physicians are ready for genomic medicine. Science Translational Medicine, 2015, 7, 287fs19.	5.8	54
190	Knowledge of Pediatric Ethics: Results of a Survey of Pediatric Ethics Consultants. AJOB Empirical Bioethics, 2015, 6, 19-30.	0.8	2
191	IRB practices and policies regarding the secondary research use of biospecimens. BMC Medical Ethics, 2015, 16, 32.	1.0	21
192	Promoting Informed Decision Making for Comparative Effectiveness Randomized Trials. JAMA Pediatrics, 2015, 169, 803.	3.3	12
193	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Research, 2015, 25, 305-315.	2.4	313
194	Professionally Responsible Disclosure of Genomic Sequencing Results in Pediatric Practice. Pediatrics, 2015, 136, e974-e982.	1.0	28
195	Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. JAMA Neurology, 2015, 72, 1313.	4.5	39
196	Parents are interested in newborn genomic testing during the early postpartum period. Genetics in Medicine, 2015, 17, 501-504.	1.1	38
197	Are hybrid umbilical cord blood banks really the best of both worlds?. Journal of Medical Ethics, 2015, 41, 272-275.	1.0	12
198	Summarizing polygenic risks for complex diseases in a clinical whole-genome report. Genetics in Medicine, 2015, 17, 536-544.	1.1	34

#	Article	IF	Citations
199	Ethics of Cancer Clinical Trials in Low-Resource Settings. Journal of Clinical Oncology, 2014, 32, 3192-3196.	0.8	11
200	Design, methods, and participant characteristics of the Impact of Personal Genomics (PGen) Study, a prospective cohort study of direct-to-consumer personal genomic testing customers. Genome Medicine, 2014, 6, 96.	3.6	37
201	A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Medical Genetics, 2014, 15, 134.	2.1	84
202	Guidelines for return of research results from pediatric genomic studies: deliberations of the Boston Childrenâ€™s Hospital Gene Partnership Informed Cohort Oversight Board. Genetics in Medicine, 2014, 16, 547-552.	1.1	49
203	Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. Genetics in Medicine, 2014, 16, 727-735.	1.1	60
204	O3-02-06: WHAT IS THE LONG-TERM EMOTIONAL AND BEHAVIORAL IMPACT OF GENETIC RISK ASSESSMENT FOR ALZHEIMER'S DISEASE? FINDINGS FROM THE REVEAL STUDY. , 2014, 10, P211-P211.		0
205	Comparison of multi-sample variant calling methods for whole genome sequencing. , 2014, 2014, 59-62.		11
206	Evaluating Novel Therapies During the Ebola Epidemic. JAMA - Journal of the American Medical Association, 2014, 312, 1299.	3.8	63
207	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
208	Chemotherapy Parity Laws. JAMA Internal Medicine, 2014, 174, 1721.	2.6	11
209	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. American Journal of Human Genetics, 2014, 94, 818-826.	2.6	342
210	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine, 2014, 20, 682-688.	15.2	508
211	Hospital Length of Stay in the First 100ÂDays after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. Biology of Blood and Marrow Transplantation, 2014, 20, 1819-1827.	2.0	43
212	Diagnostic Clinical Genome and Exome Sequencing. New England Journal of Medicine, 2014, 370, 2418-2425.	13.9	488
213	The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials, 2014, 15, 85.	0.7	122
214	O3-02-01: DIRECT-TO-CONSUMER GENETIC TESTING FOR RISK OF ALZHEIMER'S DISEASE (AD): THE PSYCHOLOGICAL AND BEHAVIORAL IMPACT OF APOE GENOTYPE DISCLOSURE. , 2014, 10, P209-P209.		1
215	Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Blood, 2014, 124, 209-209.	0.6	0
216	ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 2013, 15, 565-574.	1.1	2,186

#	Article	IF	Citations
217	How could disclosing incidental information from whole-genome sequencing affect patient behavior?. Personalized Medicine, 2013, 10, 377-386.	0.8	14
218	Relationship between Serum and Brain Carotenoids,<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold-italic">Î±</mml:mi></mml:mrow></mml:math>-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study. Journal of Aging Research, 2013, 2013, 1-13.	0.4	213
219	Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine, 2013, 15, 860-867.	1.1	99
220	Revolution or Reform in Human Subjects Research Oversight. Journal of Law, Medicine and Ethics, 2012, 40, 922-929.	0.4	8
221	Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genetics in Medicine, 2012, 14, 405-410.	1.1	149
222	Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genetics in Medicine, 2012, 14, 361-384.	1.1	418
223	O2-02-01: Caregiver Agreeableness, Neuroticism, Openness and Extraversion Associated with Cognitive Decline in Persons with Alzheimer's Disease: The Cache County Dementia Progression Study. , 2011, 7, S290-S290.		0
224	Brain levels of lutein (L) and zeaxanthin (Z) are related to cognitive function in centenarians. FASEB Journal, 2011, 25, 975.21.	0.2	14
225	Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>. JAMA - Journal of the American Medical Association, 2009, 302, 2557.	3.8	542
226	Disclosure ofAPOEGenotype for Risk of Alzheimer's Disease. New England Journal of Medicine, 2009, 361, 245-254.	13.9	490
227	A New Scale Measuring Psychologic Impact of Genetic Susceptibility Testing for Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2009, 23, 50-56.	0.6	28
228	The Genetic Privacy of Presidential Candidates. New England Journal of Medicine, 2008, 359, 2192-2193.	13.9	10
229	Health Behavior Changes After Genetic Risk Assessment for Alzheimer Disease: The REVEAL Study. Alzheimer Disease and Associated Disorders, 2008, 22, 94-97.	0.6	203
230	Statin use and the risk of Alzheimer's disease: The MIRAGE Study. , 2006, 2, 96-103.		48
231	Primary prevention trials in Alzheimer disease. Neurology, 2006, 67, S2-5.	1.5	18
232	Informed consent from the doctor?. Hastings Center Report, 2004, 34, 12; discussion 12-3.	0.7	0
233	Depression as a Risk Factor for Alzheimer Disease. Archives of Neurology, 2003, 60, 753.	4.9	485
234	Risk of Dementia Among White and African American Relatives of Patients With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2002, 287, 329.	3.8	330

#	Article	IF	Citations
235	Infusional cisplatin plus cyclophosphamide in advanced ovarian cancer. Cancer, 1986, 58, 2389-2392.	2.0	8
236	5-fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study. Cancer, 1985, 56, 2395-2398.	2.0	15